Gouvernance Veloxis Pharmaceuticals A/S

VELO

DK0060048148

Produits pharmaceutiques

Temps Différé Nasdaq Copenhagen			Varia. 5j.	Varia. 1 janv.
- ^DKK	-.--%		-.--%	-0,50%

30/05/24	Veloxis Pharmaceuticals A/S choisit de présenter ses travaux au 2024 American Transplant Congress à Philadelphie	CI
28/06/22	Veloxis Pharmaceuticals annonce le dosage du premier patient par son partenaire Xenikos dans l'étude mondiale de phase 3 évaluant T-Guard(R) chez les patients atteints de la maladie aiguë du greffon contre l'hôte réfractaire aux stéroïdes (SR-aGVHD)	CI

Comité Exécutif: Veloxis Pharmaceuticals A/S

Dirigeant

Fonctions occupéesDepuis

Daisuke Matsuo

Chief Executive Officer

Rita L. Mannella

Human Resources Officer

01/01/2017

Ulf Meier-Kriesche

Chief Tech/Sci/R&D Officer

13/09/2017

Stacy Wheeler

Chief Operating Officer

01/03/2016

Noel Barnard

General Counsel

01/03/2016

Composition du Conseil d'Administration: Veloxis Pharmaceuticals A/S

Administrateur

ComitésDepuis

Keigo Nakatsukasa

Chairman

Yusuke Hiramatsu

Director/Board Member

Anciens Dirigeants et Administrateurs: Veloxis Pharmaceuticals A/S

Insider

Fonctions occupées

DepuisJusqu'au

Ira Duarte

Comptroller/Controller/Auditor	01/02/2016	01/01/2023
Director of Finance/CFO	24/09/2018	01/01/2023
Public Communications Contact	-	01/01/2023

Craig Collard

Chief Executive Officer	10/12/2015	01/12/2021
President	10/12/2015	01/12/2021

Mark Hensley

Corporate Officer/Principal	03/01/2019	01/01/2021
Sales & Marketing	01/04/2016	03/01/2019

Robert Radie

Director/Board Member	01/06/2016	01/02/2020
Independent Dir/Board Member	01/06/2016	01/02/2020

Michael Heffernan

Director/Board Member	01/03/2015	07/04/2016
Chairman	07/04/2016	01/02/2020
Independent Dir/Board Member	01/03/2015	01/02/2020

Paul Wotton

Director/Board Member	28/07/2016	01/01/2020
Independent Dir/Board Member	28/07/2016	01/01/2020

Mette Agger

Director/Board Member	07/04/2016	01/12/2018
Chairman	26/03/2015	07/04/2016
Independent Dir/Board Member	01/04/2010	01/12/2018

Morten Marott

Director of Finance/CFO

03/04/2018

24/09/2018

Alastair Stuart McEwan

Chief Operating Officer	29/02/2016	20/09/2017
Investor Relations Contact	29/02/2016	20/09/2017
Public Communications Contact	29/02/2016	20/09/2017

Ronald Guido

Compliance Officer	01/01/2010	01/12/2016
General Counsel	01/01/2010	01/12/2016

Johnny Stilou

Comptroller/Controller/Auditor	01/04/2008	01/08/2016
Chief Tech/Sci/R&D Officer	02/06/2011	07/06/2013
Director of Finance/CFO	02/06/2011	01/08/2016
General Counsel	02/06/2011	07/06/2013

Thomas Dyrberg

Director/Board Member	01/09/2003	28/07/2016
Independent Dir/Board Member	01/09/2003	28/07/2016

Lars Kåre Viksmoen

Director/Board Member	28/07/2016	-
Independent Dir/Board Member	28/07/2016	-

Breian Knudsen

Chief Tech/Sci/R&D Officer

01/11/2007

01/05/2016

John D. Weinberg

Chief Operating Officer	01/07/2010	29/02/2016
Public Communications Contact	02/06/2011	29/02/2016
Corporate Officer/Principal	24/05/2012	07/06/2013

William Polvino

Chief Executive Officer	03/12/2009	10/12/2015
President	03/12/2009	10/12/2015

Robert Dufour

Sales & Marketing

03/06/2014

Michelle McGuinness

General Counsel

03/06/2014

Kurt Anker Nielsen

Director/Board Member	28/04/2009	19/04/2013
Independent Dir/Board Member	01/09/2006	19/04/2013

Edward Penhoet

Director/Board Member	01/07/2011	19/04/2013
Independent Dir/Board Member	01/07/2011	19/04/2013

Kim Björnstrup

Chairman	14/04/2011	-
Independent Dir/Board Member	01/04/2011	-

Paul Edick

Director/Board Member	01/04/2008	15/05/2009
Chairman	15/05/2009	13/03/2011

Edward E. Koval

Corporate Officer/Principal

04/04/2012

Timothy Charles Melkus

Chief Operating Officer	04/04/2012	-
General Counsel	04/04/2012	-

Karin Hamberg

Chief Tech/Sci/R&D Officer

15/04/2009

Anderson Gaweco

Chief Tech/Sci/R&D Officer

15/04/2009

James New

Chief Executive Officer	27/11/2008	01/01/2009
President	27/11/2008	-

Michael Beckert

Chief Tech/Sci/R&D Officer

01/01/2004

31/12/2008

Hans Christian Teisen

Director of Finance/CFO

01/12/2008

Flemming Ørnskov

Chief Executive Officer	-	05/06/2008
President	-	05/06/2008

Anders Götzsche

Director/Board Member	01/04/2008	-
Independent Dir/Board Member	01/04/2008	-

Christina Sylvest

Corporate Officer/Principal

01/04/2008

Peter Rasmussen

Director of Finance/CFO

01/01/2007

01/01/2008

Anja Leschly

Human Resources Officer	02/06/2011	-
Public Communications Contact	02/06/2011	-

Michael Wolff Jensen

Director of Finance/CFO

01/01/2003

01/01/2008

Francesca DeMartino

Public Communications Contact

04/09/2007

Lotte Sønderbjerg

Director of Finance/CFO	01/01/2003	01/01/2007
Human Resources Officer	01/01/2003	01/01/2007

Peter Schøtt Knudsen

Public Communications Contact	01/01/2007	-
General Counsel	24/05/2010	-

Jan Mikkelsen

Chief Executive Officer	01/01/2002	01/01/2006
President	01/01/2002	01/01/2006

Gérard Soula

Director/Board Member

01/11/2005

Jean Deleage

Director/Board Member

01/06/2005

Ole Pedersen

Corporate Officer/Principal

Leif Helth Jensen

Corporate Officer/Principal

Andreas Konar

Corporate Officer/Principal

A. Mark Dyas

Corporate Officer/Principal

Larry Chodoff

Chief Tech/Sci/R&D Officer

Vincenza Nigro

Chief Tech/Sci/R&D Officer

Robert Gordon

Chief Tech/Sci/R&D Officer

Claus Tycho Bræstrup

Chairman

Masaya Etoh

Director/Board Member	-	-
Independent Dir/Board Member	-	-

Matthew Ryan Dumont

Director/Board Member	-	-
Independent Dir/Board Member	-	-

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	5
Femme	2

Dont comité exécutif

Homme	3
Femme	2

Dont Administrateurs

Homme	2
Femme	0

Veloxis Pharmaceuticals A/S est une société pharmaceutique spécialisée basée au Danemark et en phase de commercialisation. Le produit de la société, Envarsus XR (comprimés de tacrolimus à libération prolongée), est un médicament délivré sur ordonnance, utilisé avec d'autres médicaments pour aider à prévenir le rejet d'organes chez les personnes ayant subi une transplantation rénale. Il est basé sur la technologie d'administration brevetée de la société, MeltDose, qui est conçue pour améliorer l'absorption et la biodisponibilité de certains médicaments administrés par voie orale. La société exerce ses activités aux États-Unis par l'intermédiaire de sa filiale Veloxis Pharmaceuticals Inc.

Employés

Secteur

Produits pharmaceutiques

Plus d'informations sur la société